Dawn Bell is Chief Scientific Officer and VP Medical Affairs at Novartis Canada.
In this role, she leads all aspects of clinical development and medical affairs and heads a team of more than 150 scientists, healthcare professionals, and support staff. Prior to this, she was Senior Global Program Head in Novartis Global Development, where she was responsible for global registration and commercialization of a multibillion dollar heart-failure asset that achieved fast-track review from the FDA and the EMA, accelerating launch by one year.
Prior to Novartis, Dawn founded Cool~Bio, a privately held, preclinical-stage company focused on developing a novel hypothermia-activated fusion protein to prevent platelet activation during cardiac surgery. Before that, she was US General Manager for Canyon Pharmaceuticals, a privately held, commercial-stage biotechnology company, where she developed and executed business strategy, resulting in a US licensing agreement for Iprivask, a novel anticoagulant. Prior to Canyon, Dawn held various roles of increasing responsibility in market access, medical affairs, and clinical development at The Medicines Company, a publically traded, hospital-products company.
Dawn earned her Doctor of Pharmacy degree from the University of Florida and completed postgraduate residency training at the University of Illinois at Chicago and a post-graduate fellowship in Cardiovascular Medicine at the University of Florida, focusing on the pharmacogenomics of heart failure. Prior to joining industry, Dawn was a tenured associate professor at West Virginia University, where she maintained an active research and teaching program in cardiovascular medicine.